• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

EpiAxis Therapeutics

Monday, June 03, 2024
CP
Oncology
EpiAxis Therapeutics is a pre-clinical stage company that uses an innovative epigenetics approach which is focused on addressing the critical challenge of overcoming cancer treatment resistance and preventing cancer recurrence. Our lead drug candidate, epiresatide (METPENZA™), is a promising therapy for difficult to treat cancers. It is an AI-designed synthetic peptide which can restore transcriptional balance and has first-to-market potential as a CoRest Complex disruptor. It is positioned for combination usage with SoC therapies in difficult to treat cancers. Three indications are being advanced: mucinous adenocarcinoma (MAC) of the colon and rectum, CNS tumours, and triple negative breast cancer (TNBC). These indications all have a very high un-met clinical need, with only marginal improvements observed with current therapeutics approaches.
EpiAxis Therapeutics
Company Website: http://www.epiaxistherapeutics.com
Lead Product in Development: Epiresatide
Number Of Unlicensed Products (For Which You Are Seeking Partners): `1

Website

http://www.epiaxistherapeutics.com

Company HQ City

Sydney

Company HQ State

NSW

Company HQ Country

Australia

CEO/Top Company Official

Dr Jeremy S Chrisp

Lead Product in Development

Epiresatide

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS